

339 | 6

Views CrossRef citations to date Altmetric

81


Perspectives

Convergence of decision rules for value-based pricing of new innovative drugs

Afschin Gandjour 

Pages 209-213 | Published online: 18 Oct 2014

 Cite this article  <https://doi.org/10.1586/14737167.2015.972374>

 Check for updates

Sample our
Bioscience
Journals
>> **Sign in here** to start your access
to the latest two volumes for 14 days

 Full Article

 Figures & data

 References

 Citations

 Metrics

 Reprints & Permissions

Read this article

Abstract

Given the high costs of innovative new drugs, most European countries have introduced... and

international... profit-
maximizing... these
policies... ching
sequenc... s volume in
any give... e in
inter... nale, it is
best for... et cost-
effective... This way,
international... lowest
accepta...

We Care About Your Privacy

We and our 842 partners store and/or access information on a device, such as unique IDs in cookies to process personal data. You may accept or manage your choices by clicking below, including your right to object where legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our partners and will not affect browsing data. [Privacy Policy](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.

List of Partners (vendors)

I Accept

Essential Only

Show Purpose



Acknowledgements

The author would like to thank three anonymous reviewers for very helpful comments on an earlier draft.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Key issues

- Given the high costs of innovative new drugs, most European countries have introduced policies for price control, in particular value-based pricing (VBP) and international reference pricing (IRP).
- The author argues that the current regulatory framework is not sufficiently flexible to allow for the implementation of VBP and IRP, and that a more flexible framework is needed to allow for the implementation of VBP and IRP.
- To address this issue, the author proposes a new regulatory framework that would allow for the implementation of VBP and IRP, and that would also address the issue of the implementation of VBP and IRP.
- The author argues that the current regulatory framework is not sufficiently flexible to allow for the implementation of VBP and IRP, and that a more flexible framework is needed to allow for the implementation of VBP and IRP.
- As a result, the author argues that the current regulatory framework is not sufficiently flexible to allow for the implementation of VBP and IRP, and that a more flexible framework is needed to allow for the implementation of VBP and IRP.



- In the long term, it is best for VBP countries in Europe to implicitly collude and set cost-effectiveness thresholds at the level of the lowest acceptable VBP country.
- In response, manufacturers might support initiatives for differential pricing according to national income and ability to pay.

Notes

Related research

People also read

Recommended articles

Cited by
6

Value elements and methods of value-based pricing for drugs in Japan: a systematic review >

Akina Takami et al.
Expert Review of Pharmacoeconomics & Outcomes Research
Published online: 20 Jun 2023

Pricing > t choices >

Katarzy
Expert R
Publishe



Peter H
Expert R
Publishe

Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Help and contact

Newsroom

All journals

Books

Keep up to date

Register to receive personalised research and resources by email



Sign me up



Copyright © 2024 Informa UK Limited [Privacy policy](#) [Cookies](#) [Terms & conditions](#)



Taylor & Francis Group
an informa business

Accessib



Registered
5 Howick Pl

